Featured Research

from universities, journals, and other organizations

No impact of age on outcome in chronic myeloid leukemia patients treated with imatinib, study suggests

Date:
March 30, 2011
Source:
American Society of Hematology
Summary:
While the median age at diagnosis for chronic myeloid leukemia (CML) is over 60 years old, limited data are available about the long-term outcome for older patients treated with imatinib, the standard first-line therapy used to treat CML. New results, however, reveal that age does not affect response to imatinib and overall survival is similar in older and younger patients treated with the drug.

While the median age at diagnosis for chronic myeloid leukemia (CML) is over 60 years old and incidence increases dramatically with age,limited data are available about the long-term outcome for older patients treated with imatinib, the standard first-line therapy used to treat CML. Results from a study published March 29 in Blood, the Journal of the American Society of Hematology, reveal that age does not affect response to imatinib and study investigators conclude that overall survival for CML is similar in older and younger patients treated with the drug.

Two widely used prognostic scores for CML, the Sokal and EURO risk scores, have historically identified older age as a predicting factor of lower response rate and poorer outcome. However, these risk scores were validated before imatinib was introduced as a therapy for CML and may now hold less relevance, as imatinib has dramatically improved the prognosis for CML patients.

"Older age has typically been considered a poor prognostic factor in patients with CML and has a negative impact on response rates and long-term survival, regardless of treatment," said Gabriele Gugliotta, MD, co-author of the study and Fellow in the Department of Hematology and Oncology at St. Orsola-Malpighi Hospital at the University of Bologna in Bologna, Italy. "Our study focused on disease progression, treatment response, and survival of this specific patient population to assess the role of imatinib in older patients."

To test whether age at diagnosis is a valid predictor of response, researchers from several institutions in Italy conducted an analysis of 559 patients with early chronic phase CML (six months or less from diagnosis to start of imatinib treatment) who were enrolled in three concurrent clinical trials in the Gruppo Italiano Malattie Ematologiche dell'Adulto CML Working Party, between May 2003 and April 2007. Trial participants over age 65 were defined as "older" patients and those under age 65 were classified as "younger" patients.

Results from the patient analysis revealed that complete hematologic response, or a return to normal blood cell and platelet counts, was observed at three-month follow-up in 97 percent of the older age group and 96 percent of the younger age group. At six, 12, and 24 months follow-up, 69 percent, 78 percent, and 74 percent of older patients and 67 percent, 77 percent, and 78 percent of younger patients, respectively, achieved complete cytogenetic response, or the point when no leukemic cells are detected in the blood. As for long-term survival, after discounting deaths unrelated to CML in both the older and younger patients, researchers found no significant difference in mortality rates between the two age groups. The adjusted overall survival rate for the older patients was 94 percent, compared to 96 percent for the younger patients (p=0.4), further demonstrating that age was not a significant factor in imatinib response and did not affect patient survival.

"This is the first study that has specifically analyzed the long-term outcome of older patients with early chronic phase CML treated with imatinib," said Gianantonio Rosti, MD, lead study author and hematologist in the Department of Hematology and Oncology at St. Orsola-Malpighi Hospital at the University of Bologna. "While increasing age is generally associated with higher mortality, the results of our analysis demonstrate that when it comes to treating CML patients, older age must not be a limitation for treatment with imatinib, as it is a very effective therapy for this patient population."


Story Source:

The above story is based on materials provided by American Society of Hematology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Gabriele Gugliotta et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML WP. Blood, March 30, 2011 DOI: 10.1182/blood-2010-12-324228

Cite This Page:

American Society of Hematology. "No impact of age on outcome in chronic myeloid leukemia patients treated with imatinib, study suggests." ScienceDaily. ScienceDaily, 30 March 2011. <www.sciencedaily.com/releases/2011/03/110330131348.htm>.
American Society of Hematology. (2011, March 30). No impact of age on outcome in chronic myeloid leukemia patients treated with imatinib, study suggests. ScienceDaily. Retrieved July 26, 2014 from www.sciencedaily.com/releases/2011/03/110330131348.htm
American Society of Hematology. "No impact of age on outcome in chronic myeloid leukemia patients treated with imatinib, study suggests." ScienceDaily. www.sciencedaily.com/releases/2011/03/110330131348.htm (accessed July 26, 2014).

Share This




More Health & Medicine News

Saturday, July 26, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins